SCHEDULE: Janus Henderson Discloses 9.6% Stake in Protara Therapeutics

Janus Henderson Group plc has reported beneficial ownership of 5,207,011 shares, representing 9.6% of Protara Therapeutics, Inc.'s common stock, as of March 31, 2026.

Summary

• Janus Henderson Group plc, through its various asset management subsidiaries, has disclosed a significant beneficial ownership stake in Protara Therapeutics, Inc.
• The filing indicates that as of March 31, 2026, Janus Henderson Group plc, via its asset managers, beneficially owns 5,207,011 shares of Protara Therapeutics, Inc. common stock.
• This holding represents 9.6% of the total class of securities.
• The asset managers exercise investment and/or voting discretion on behalf of clients, including investment companies, other investment advisers, and separate accounts.
• Janus Henderson Group plc disclaims beneficial ownership of dividends and proceeds from the sale of these securities, as these rights belong to the managed portfolios.
• The Janus Henderson Biotech Innovation Master Fund Ltd. is specifically mentioned as having the right to receive dividends and sale proceeds for more than five percent of the common stock, but is not considered a Reporting Person due to delegation of discretion.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive indicator, as a major investment firm taking a significant stake suggests confidence, but the filing itself is purely a disclosure without performance data.

Positives

• Janus Henderson Group plc, a significant investment management firm, has taken a substantial stake in Protara Therapeutics, Inc., indicating confidence in the company's prospects.
• The 9.6% ownership stake suggests a notable level of investment and potential influence.
• The filing clarifies the structure of beneficial ownership, highlighting the role of various asset management subsidiaries.

Negatives

• The filing does not contain any negative financial results or operational issues for Protara Therapeutics, Inc. itself, as it is a Schedule 13G filing focused on ownership.
• Janus Henderson Group plc disclaims direct ownership of dividends and sale proceeds, attributing these rights to the managed portfolios.

Risks

• The primary risk associated with this filing is the potential for significant share price movement if Janus Henderson Group plc decides to alter its substantial stake.
• While not explicitly stated as a risk in this filing, a large institutional holder's trading activity can influence market perception and stock price volatility.

Future Outlook

This filing is a disclosure of current ownership and does not contain forward-looking statements or guidance from Protara Therapeutics, Inc. or Janus Henderson Group plc regarding future performance.

Management Comments

• Janus Henderson Group plc, through its appointed attorneys-in-fact, certifies that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that significant stake disclosures by large asset managers like Janus Henderson Group plc in biotechnology companies are common, reflecting active portfolio management and strategic investment in sectors with high growth potential and specific innovation pipelines.

Stakeholder Impact

• Shareholders of Protara Therapeutics, Inc. may see increased attention on the stock due to the significant stake held by a large institutional investor.
• Potential for increased trading volume and price volatility as the market reacts to the disclosure of a major holder.

Next Steps

• Janus Henderson Group plc will continue to hold its shares in Protara Therapeutics, Inc. unless it decides to change its investment position.
• Protara Therapeutics, Inc. will continue its business operations and strategic initiatives.

Key Dates

Keywords

Protara Therapeutics, Janus Henderson Group, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, SEC Filing, Institutional Investor, Biotech